Cosmos Health Inc. (NASDAQ: COSM), a diversified, vertically integrated global healthcare group, has officially announced its expansion into the veterinary and animal health sector. The milestone marks the company’s first entry into the rapidly growing animal health market, driven by the planned launch of a specialized veterinary formulation of its established antimicrobial brand, C-Scrub Wash 4%.
The initial commercial rollout is strategically targeted for the United Kingdom, a region where C-Scrub is already an active and trusted brand in human healthcare. Following the UK launch, Cosmos Health intends to execute a broader international expansion to capture a share of the global veterinary disinfectant market.
Rigorous EU Efficacy Standards Met
The decision to cross over into animal health follows successful independent laboratory testing conducted by Quality Assurance & Control Systems Ltd. (QACS), an EU-based testing facility accredited to EN ISO/IEC 17025:2017.
Operating under strict clean conditions at 20°C with a 10-minute contact time, the formulation successfully cleared the stringent European standards required for veterinary-grade disinfectants and antiseptics:
-
Bactericidal Activity (EN 1656:2019): C-Scrub Wash 4% achieved the mandatory 99.999% reduction (destroying 99.999% of targeted bacterial cells) against four primary veterinary pathogens: Pseudomonas aeruginosa, Staphylococcus aureus, Proteus hauseri, and Enterococcus hirae. Efficacy was proven at both undiluted (80%) and 50% concentrations
-
Yeasticidal Activity (EN 1657:2024): The product successfully met all European criteria for evaluating yeasticidal activity in the veterinary field, proving its multi-spectrum capability against fungal pathogens under clinical conditions.
